8 February 2016 - Pricing of licensed, newer vaccines generally far exceeds production costs, but revenue drives future vaccine development. The difficult question becomes what is a reasonable return on investment?

For more details, go to: http://jama.jamanetwork.com/article.aspx?articleID=2491460&utm_source=Silverchair%20Information%20Systems&utm_medium=email&utm_campaign=JAMA%3AOnlineFirst02%2F08%2F2016